Clinical Trial Update: An Open-Label Study of Atomoxetine in Adolescents With Attention-Deficit/Hyperactivity Disorder [Phase 3]

View source ↗

Summary

An open-label Phase 3 study evaluating atomoxetine in adolescents with Attention Deficit Hyperactivity Disorder has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder

Drugs mentioned

• STRATTERA (Atomoxetine hydrochloride)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Attention Deficit Hyperactivity Disorder | Phase 3 | Status: COMPLETED